Abstract
We report a case of massive submacular hemorrhage (SMH) in a patient with neovascular age-related macular degeneration (AMD) occurring three days after intravitreal faricimab injection. While faricimab has demonstrated a favorable safety profile and lower hemorrhagic events compared to other anti-vascular endothelial growth factor agents, SMH, in specific, is not listed among the significant adverse events in available clinical trial safety data or in postmarketing pharmacovigilance analyses. This case highlights a new severe hemorrhagic complication that can cause permanent visual damage related to faricimab even in well-monitored patients.